Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenue | 18,265 | 14,108 |
| Operating Expenses | ||
| Cost of product sales | 262 | — |
| Research and development | 65,263 | 55,973 |
| Selling, general and administrative | 31,555 | 22,835 |
| Total operating expenses | 97,080 | 78,808 |
| Loss from operations | (78,815) | (64,700) |
| Other Income (Expense) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's R&D?
- Kura Oncology (KURA) reported R&D of $65.26M in Q1 2026.
- How has Kura Oncology's R&D changed year-over-year?
- Kura Oncology's R&D increased by 16.6% year-over-year, from $55.97M to $65.26M.
- What is the long-term trend for Kura Oncology's R&D?
- Over 4 years (2021 to 2025), Kura Oncology's R&D has grown at a 31.2% compound annual growth rate (CAGR), from $84.72M to $251.07M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Kura Oncology's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude